New drug before prostate surgery: a step toward better cancer control?

NCT ID NCT06613100

Recruiting now Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Nov 12, 2025 · Last updated May 08, 2026 · Updated 25 times

Summary

This study tests a new drug called xaluritamig, given alone or with hormone therapy, before prostate removal surgery in men with intermediate or high-risk prostate cancer. The goal is to see if the drug is safe and if surgery afterward is still possible. About 40 men will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109-1023, United States
Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
The Ohio State University
RECRUITING

Columbus, Ohio, 43210, United States
Thomas Jefferson University
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
Universitaetsklinikum Essen
RECRUITING

Essen, 45147, Germany
Universitaetsklinikum Hamburg Eppendorf
RECRUITING

Hamburg, 20246, Germany
University of California San Francisco
RECRUITING

San Francisco, California, 94143, United States
Washington University
RECRUITING

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

PROSTATE CANCER